.........This work is potentially very important, as it could be a last way out for patients that have become resistant to rituximab. If those patients receive an injection of 177Lu-lilotomab-satetraxetan, they can be treated again with rituximab and have an improved effect. In a phase 1b clinical trial, a 100 percent complete response rate was achieved in the first group of patients treated with 177Lu-lilotomab-satetraxetan followed by rituximab. Achieving a complete response is very important, since it usually correlates with an improved duration of response and overall survival."

Dr. Jostein Dahle, PhD, Chief Scientific Officer at Nordic Nanovector

Les mer

https://www.news-medical.net/news/20201008/Novel-radioimmunotherapy-proven-effective-in-reversing-resistance-to-lymphoma-therapy.aspx